Tag Archives: Orphan Drugs

Orphan Drug Market to Reach $176 Billion by 2020, Says Report

By 2020, orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to EvaluatePharma’s Orphan Drug Report 2014. At 11 percent, this growth is set to be more than double the 5 percent growth rate of the overall prescription market, […]
Posted in Global, Orphan Drugs | Also tagged , , | Leave a comment

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals. The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and […]
Posted in Orphan Drugs, pricing | Also tagged , | Leave a comment

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

PharmExec's Orphan Drug Pipeline Picks

Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years. In the US, private and government payers haven’t yet had the nerve to balk at rare disease drug prices. […]
Posted in Global, Orphan Drugs, pricing, R&D, Regulatory, Sales, Strategy | Tagged | Leave a comment

The List So Far: FDA Breakthrough Designations

With announcements pouring in since the beginning of this year, FDA’s fourth and newest expedited approval pathway for medicines has begun to bear fruit. Established in 2012 within the FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designations have so far totaled 25 as of the end of July. With a separate senior management team […]
Posted in Biotech, FDA, Orphan Drugs, Regulatory | Also tagged , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta